Soleno Therapeutics (SLNO) Cash & Equivalents (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Equivalents data on file, last reported at $133.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 63.53% year-over-year to $133.0 million in Q1 2026; TTM through Mar 2026 was $133.0 million, a 63.53% increase from a year earlier, with the FY2025 full-year figure at $70.1 million, down 20.27% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $133.0 million, up from $70.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SLNO reached as high as $246.7 million in Q3 2025 and fell as low as $7.9 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $69.4 million across 5 years, with a median of $52.4 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 1062.04% in 2023 and fell as far as 72.73% in 2023.
• Year by year, Cash & Equivalents stood at $14.6 million in 2022, then surged by 1062.04% to $169.7 million in 2023, then plunged by 48.18% to $87.9 million in 2024, then decreased by 20.27% to $70.1 million in 2025, then jumped by 89.71% to $133.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $133.0 million in Q1 2026, $70.1 million in Q4 2025, and $246.7 million in Q3 2025.